AptarGroup, Inc.
Thesis
AptarGroup is well-positioned to benefit from the growing demand for sterile packaging in the pharmaceutical sector, particularly with its elastomeric components. The company is expected to achieve high-single digit organic growth in its pharma segment, driven by drug repurposing and increasing biologic production in APAC. Additionally, Aptar's unique ability to transfer technology across its segments creates a competitive advantage that supports long-term growth and margin expansion.
Did it work?
The thesis anticipated high-single digit organic growth in AptarGroup's pharma segment, but the stock has only returned -1.0% over 28 months, indicating that the expected growth and competitive advantages have not materialized as projected. Given the time elapsed, the lack of positive price performance suggests that the company's growth drivers have not been effective, leading to a failure of the investment thesis.
Raw excerpt
No raw excerpt stored.